Long-term effects of interferon-based therapy for chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Oncology

Background:

• Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).
• Liver transplantation is frequently necessitated by end-stage liver disease due to HCV.
• Interferon (IFN)-based therapies have been standard for viral clearance in chronic hepatitis C (CHC).

Purpose of the Study:

• To evaluate the long-term benefits of interferon-based therapies in preventing liver disease progression and complications in CHC patients.
• To determine if the benefits of antiviral treatment are regimen-dependent or primarily linked to treatment response.
• To highlight the need for more effective treatments for patients resistant to current regimens.

Main Methods:

• Review of earlier studies on IFN monotherapy and IFN-ribavirin combination therapy for CHC.
• Analysis of long-term outcomes, including cirrhosis progression, HCC development, and mortality.
• Assessment of the impact of sustained virological response (SVR) on treatment benefits.

Main Results:

• IFN-based therapies, including monotherapy and combination therapy, reduce liver disease complications like cirrhosis and HCC.
• The observed benefits are primarily associated with achieving a sustained virological response (SVR), not the specific antiviral regimen.
• Patients without SVR did not show long-term benefits in disease progression prevention.
• Approximately one-third of patients remain resistant to current standard antiviral treatments.

Conclusions:

• The preventive effects of antiviral treatment for CHC are strongly linked to achieving SVR.
• Improving SVR rates through more effective regimens, like peginterferon-ribavirin, could enhance preventive benefits.
• There is a significant unmet need for novel, effective treatments for HCV patients resistant to current therapies.